WorkshopBeyond the International Harmonization Criteria – New challenges in the application of imaging techniques for staging and response
Andreas Engert
Kara Kelly
Judith Landman-Parker
Practical experience in the application of the International Harmonization Criteria – as viewed by a medical oncologist
Anas Younes
Anatomic imaging challenges of the International Harmonization Criteria
Lawrence H. Schwartz
Nuclear medicine aspects of the International Harmonization Criteria, as they apply to pediatrics
Regine Kluge
Overview of the challenges encountered by the Pediatric International Harmonization Criteria Workshop
Kara Kelly
Discussion
Dieter Körholz
09:00 – 10:30
Room: Großer Saal
Scientific SessionSurvivorship
Jonathan Friedberg
Lena Specht
Cardiac toxicity
Judith Landman-Parker
Breast Cancer and other Neoplasms
Berthe Aleman
Fertility
Karolin Behringer
Changes in breast cancer risk as long-term Hodgkin Lymphoma survivors reach menopausal age
Julia S. Wong
Second cancer risk forty years a er cure for Hodgkin Lymphoma
Michael Schaapveld
A Dutch nationwide survivorship care programme for Hodgkin Lymphoma survivors
Flora van Leeuwen
11:00 – 12:30
Room: Großer Saal
Scientific SessionAdvanced Stages
Richard Fisher
Franck Morschhauser
Risk-adapted therapy in advanced stage Hodgkin Lymphoma: An Update
Massimo Federico
Can we improve ABVD?
Stephen Ansell
Can we improve BEACOPP?
Peter Borchmann
Impact of dose reductions of bleomycin and vincristine in patients with advanced Hodgkin Lymphoma treated with BEACOPP polychemotherapy:
A comprehensive analysis of the German Hodgkin Study Group (GHSG) HD12 and HD15 trials
Bastian von Tresckow
Standard ABVD vs. escalated BEACOPP in stage III – IV low risk Hodgkin Lymphoma (IPS 0-2): the Lymphoma Study Association (LYSA) H34 trial
Nicolas Mounier
Response rates and toxicity of response-adapted therapy in advanced Hodgkin Lymphoma: initial results from the international RATHL study
Peter Johnson
12:45 – 14:15
Room: Großer Saal
Satellite SymposiumUpdate on Infectious Diseases in Hematology Patients
Oliver A. Cornely
Introduction
Clinical infectious challenges in patients with Hodgkin Lymphoma
Livio Pagano
Present and upcoming vaccines for the immunocomprised host
Per Ljungman
Focussing on unmet medical needs in abdominal infections
Maria J. Vehreschild
Discussion and Summary
Oliver A. Cornely
13:45 – 14:15
Room: Kleiner Saal
Main ProgramPoster Walk
14:30 – 16:00
Room: Großer Saal
Scientific SessionRelapsed
Christian Gisselbrecht
Anna Sureda
What’s new in relapsed Hodgkin Lymphoma?
Bastian von Tresckow
Debate: Is there still a role for allogeneic
TX in Hodgkin Lymphoma?
Patrice Carde
Anton Hagenbeek
Karl Peggs
Phase 2 study everolimus for relapsed / refractory classical Hodgkin Lymphoma (cHL)
Patrick Johnston
Outcome of patients treated with autologous stem-cell transplantation for rst relapsed or refractory Hodgkin Lymphoma: A long-term analysis of the prospective LYSA / SFGM-TC H96 trial
Patrick Johnston
PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin Lymphoma